Inserm

[{"orgOrder":0,"company":"Inserm","sponsor":"Advanced Accelerator Applications","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"99m-Tc Annexin V-128","moa":"Apoptosis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ Advanced Accelerator Applications","highestDevelopmentStatusID":"7","companyTruncated":"Inserm \/ Advanced Accelerator Applications"},{"orgOrder":0,"company":"Inserm","sponsor":"University of Liverpool | Cardiff University | University of Nottingham | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf | Assistance Publique \u2013 H\u00f4pitaux de P","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ University of Liverpool | Cardiff University | University of Nottingham | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf | Assistance Publique \u2013 H\u00f4pitaux de P","highestDevelopmentStatusID":"10","companyTruncated":"Inserm \/ University of Liverpool | Cardiff University | University of Nottingham | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf | Assistance Publique \u2013 H\u00f4pitaux de P"},{"orgOrder":0,"company":"Inserm","sponsor":"Inserm","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CTL19","moa":"CD19","graph1":"Hematology","graph2":"Phase I","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inserm \/ INSERM","highestDevelopmentStatusID":"6","companyTruncated":"Inserm \/ INSERM"},{"orgOrder":0,"company":"Inserm","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"GLUT1 DS","moa":"GLUT1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Inserm \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Inserm","sponsor":"EVI Industries | BPRC | Paris Descartes Necker Cochin Sainte Anne Clinical Research | Centre national de recherche et de formation sur le paludisme","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"AMA1-DiCo","moa":"Malaria protein EXP-1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ EVI Industries | BPRC | Paris Descartes Necker Cochin Sainte Anne Clinical Research | Centre national de recherche et de formation sur le paludisme","highestDevelopmentStatusID":"6","companyTruncated":"Inserm \/ EVI Industries | BPRC | Paris Descartes Necker Cochin Sainte Anne Clinical Research | Centre national de recherche et de formation sur le paludisme"},{"orgOrder":0,"company":"Inserm","sponsor":"T.H.A.C.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"ALF-5755","moa":"Regenerating human pro-islet peptide (REG3A)","graph1":"Endocrinology","graph2":"Phase I","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ T.H.A.C.","highestDevelopmentStatusID":"6","companyTruncated":"Inserm \/ T.H.A.C."},{"orgOrder":0,"company":"Inserm","sponsor":"Fujifilm Toyama Chemical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inserm \/ Fujifilm Toyama Chemical","highestDevelopmentStatusID":"6","companyTruncated":"Inserm \/ Fujifilm Toyama Chemical"},{"orgOrder":0,"company":"Inserm","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"||RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ World Health Organization","highestDevelopmentStatusID":"10","companyTruncated":"Inserm \/ World Health Organization"},{"orgOrder":0,"company":"Inserm","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Triheptanoin","moa":"Triglyceride","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oil","sponsorNew":"Inserm \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Inserm \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Inserm","sponsor":"Commissariat A L'energie Atomique | Institut Bergoni\u00e9 | Plateforme labellis\u00e9e Inca - Institut Bergoni\u00e9 | Plateforme labellis\u00e9e Inca - H\u00f4pital Pompidou | EUCLID Clinical Trial Platform","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase III","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ Commissariat A L'energie Atomique | Institut Bergoni\u00e9 | Plateforme labellis\u00e9e Inca - Institut Bergoni\u00e9 | Plateforme labellis\u00e9e Inca - H\u00f4pital Pompidou | EUCLID Clinical Trial Platform","highestDevelopmentStatusID":"10","companyTruncated":"Inserm \/ Commissariat A L'energie Atomique | Institut Bergoni\u00e9 | Plateforme labellis\u00e9e Inca - Institut Bergoni\u00e9 | Plateforme labellis\u00e9e Inca - H\u00f4pital Pompidou | EUCLID Clinical Trial Platform"},{"orgOrder":0,"company":"Inserm","sponsor":"MCM Vaccines","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"Inactivated Non Adjuvanted Pandemic H1N1 Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ MCM Vaccines","highestDevelopmentStatusID":"8","companyTruncated":"Inserm \/ MCM Vaccines"},{"orgOrder":0,"company":"Inserm","sponsor":"European Vaccine Initiative | Paris Descartes Necker Cochin Sainte Anne Clinical Research | Centre national de recherche et de formation sur le paludisme | EUCLID Clinical Trial Platform","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Placental Malaria Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ European Vaccine Initiative | Paris Descartes Necker Cochin Sainte Anne Clinical Research | Centre national de recherche et de formation sur le paludisme | EUCLID Clinical Trial Platform","highestDevelopmentStatusID":"6","companyTruncated":"Inserm \/ European Vaccine Initiative | Paris Descartes Necker Cochin Sainte Anne Clinical Research | Centre national de recherche et de formation sur le paludisme | EUCLID Clinical Trial Platform"},{"orgOrder":0,"company":"Inserm","sponsor":"Inserm","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"sFlt-1\/PlGF","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ INSERM","highestDevelopmentStatusID":"1","companyTruncated":"Inserm \/ INSERM"},{"orgOrder":0,"company":"Inserm","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ Inserm","highestDevelopmentStatusID":"2","companyTruncated":"Inserm \/ Inserm"}]